Medicenna Announces Results of Annual Meeting of Shareholders
Medicenna Therapeutics (OTCQX: MDNAF), a clinical-stage immunotherapy company specializing in Superkines development, held its annual shareholders meeting on September 25, 2025. The meeting saw a 55.75% turnout of issued and outstanding common shares, with all nominated directors successfully elected with overwhelming support, each receiving over 98.8% approval.
Notable changes include Dr. John H. Sampson's departure from the board, though he will continue as a clinical advisor. The election results demonstrated strong shareholder confidence, with key figures like Dr. Fahar Merchant and Ms. Karen Dawes receiving 99.25% and 99.35% of votes respectively.
Medicenna Therapeutics (OTCQX: MDNAF), una società di immunoterapia in fase clinica specializzata nello sviluppo di Superkines, ha tenuto la sua assemblea annuale degli azionisti il 25 settembre 2025. L'incontro ha registrato una partecipazione del 55,75% delle azioni ordinarie emesse e in circolazione, con tutti i direttori nominati eletti con un supporto schiacciante, ognuno ha ricevuto oltre il 98,8% di approvazione.
Tra i cambiamenti rilevanti, Dr. John H. Sampson lascia il consiglio, anche se continuerà come consulente clinico. I risultati delle elezioni hanno mostrato una forte fiducia degli azionisti, con figure chiave come Dr. Fahar Merchant e Ms. Karen Dawes che hanno ottenuto rispettivamente 99,25% e 99,35% dei voti.
Medicenna Therapeutics (OTCQX: MDNAF), una empresa de inmunoterapia en fase clínica especializada en el desarrollo de Superkines, celebró su reunión anual de accionistas el 25 de septiembre de 2025. La reunión registró una asistencia del 55,75% de las acciones comunes emitidas y en circulación, y todos los directores nominados fueron electos con un apoyo abrumador, cada uno recibiendo más del 98,8% de aprobación.
Entre los cambios destacados, el Dr. John H. Sampson se aparta de la junta, aunque continuará como asesor clínico. Los resultados mostraron una fuerte confianza de los accionistas, con figuras clave como el Dr. Fahar Merchant y la Sra. Karen Dawes obteniendo 99,25% y 99,35% de los votos, respectivamente.
Medicenna Therapeutics (OTCQX: MDNAF)는 임상기 단계의 면역요법 회사로서 Superkines 개발에 특화되어 있으며, 2025년 9월 25일에 연례 주주총회를 개최했습니다. 회의 참석률은 발행 및 유통 중인 보통주 총수의 55.75%였으며, 지명된 모든 이사진이 압도적 지지로 선출되었고, 각각 98.8% 이상의 찬성을 받았습니다.
주요 변화로는 존 H. 샘슨 박사가 이사회에서 물러나지만 임상 자문위원으로는 계속 활동한다는 점이 있습니다. 선거 결과는 주주들의 신뢰가 강하다는 것을 보여주었으며, Fahar Merchant 박사와 Karen Dawes 양은 각각 99.25%와 99.35%의 표를 받았습니다.
Medicenna Therapeutics (OTCQX: MDNAF), une société en immunothérapie en phase clinique spécialisée dans le développement des Superkines, a tenu son assemblée générale annuelle des actionnaires le 25 septembre 2025. La participation des actions ordinaires émises et en circulation s’est élevée à 55,75%, et tous les administrateurs nommés ont été élus avec un soutien écrasant, chacun recevant plus de 98,8% des voix.
Parmi les changements notables, le Dr John H. Sampson se retire du conseil, bien qu’il poursuive son rôle de conseiller clinique. Les résultats montrent une forte confiance des actionnaires, des personnalités clés comme le Dr Fahar Merchant et Mme Karen Dawes obtenant respectivement 99,25% et 99,35% des voix.
Medicenna Therapeutics (OTCQX: MDNAF), ein klinisch fortgeschrittenes Immuntherapieunternehmen, das sich auf die Entwicklung von Superkines spezialisiert hat, hielt seine jährliche Hauptversammlung der Aktionäre am 25. September 2025 ab. Die Teilnahme betrug 55,75% der ausgegebenen und umlaufenden Stammaktien, und alle nominierten Direktoren wurden mit überwältigender Unterstützung gewählt, jeder erhielt über 98,8% Zustimmung.
Zu den bemerkenswerten Änderungen gehört der Austritt von Dr. John H. Sampson aus dem Vorstand, er wird jedoch weiterhin als klinischer Berater tätig sein. Die Wahlergebnisse zeigten das starke Vertrauen der Aktionäre, mit Schlüsselpersonen wie Dr. Fahar Merchant und Ms. Karen Dawes, die 99,25% bzw. 99,35% der Stimmen erhielten.
Medicenna Therapeutics (OTCQX: MDNAF)، شركة رعاية مناعية في المرحلة السريرية متخصصة في تطوير سوبركاينز، عقدت اجتماعها السنوي للمساهمين في 25 سبتمبر 2025. شهد الاجتماع حضوراً بلغ 55,75% من إجمالي الأسهم العادية المصدرَة والمتداولة، وتم انتخاب جميع المدراء المرشحين بدعم ساحق، كل واحد منهم حصل على أكثر من 98,8% من الموافقات.
من التغييرات الملحوظة أن الدكتور جون هـ. سامسون يغادر المجلس، وإن كان سيظل مستشاراً سريرياً. أظهرت نتائج الانتخابات ثقة قوية من المساهمين، حيث حصلت شخصيات رئيسية مثل الدكتور فهر ميرشنت والدكتورة كارين داوز على 99,25% و 99,35% من الأصوات على التوالي.
Medicenna Therapeutics (OTCQX: MDNAF)，一家处于临床阶段的免疫治疗公司，专注于开发超级蛋白（Superkines），于<2025年9月25日举行了年度股东大会。发行在外普通股的出席率为55.75%，所有提名的董事均在压倒性支持下当选，每位获得超过98.8%的赞成票。
值得关注的变动包括 Dr. John H. Sampson 离任董事会，但他将继续担任临床顾问。选举结果显示股东信心强烈，关键人物如 Dr. Fahar Merchant 和 Ms. Karen Dawes 分别获得了99.25%和99.35%的投票支持。
- None.
- None.
TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the voting results from the Company’s annual meeting of shareholders held today, September 25, 2025 (the “Meeting”).
Medicenna is pleased to announce that all nominees listed in the management information circular dated August 13, 2025 (the “Circular”), were elected as directors. The results of the vote are detailed below:
| Nominee | Votes For | % of Votes For | Votes Against | % of Votes Against |
| Dr. Fahar Merchant | 35,539,547 | 266,887 | ||
| Mr. Albert Beraldo | 35,572,009 | 234,425 | ||
| Dr. John (Jack) Geltosky | 35,432,573 | 373,861 | ||
| Ms. Karen Dawes | 35,574,263 | 232,171 | ||
| Mr. Karim Lalji | 35,401,699 | 404,735 |
A total of
Dr. John H. Sampson did not stand for re-election at the meeting but will continue to support the Company in a consulting capacity as a clinical advisor. Mr. Albert Beraldo, Lead Independent Director, commented: “On behalf of my fellow board members and the Medicenna management team, I would like to thank Dr. Sampson for his dedicated service to the Company over the years, as well as for his continued expertise and support.”
Please refer to the Circular available on SEDAR+ at www.sedarplus.ca for more information on the business transacted at the Meeting. A report on voting results will also be filed on SEDAR+.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
For more information, please visit www.medicenna.com, and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially”, “equivocally,” and similar expressions and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
This news releases contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
Investor/Media Contact:
Shushu Feng
Investor Relations, Medicenna Therapeutics
(416) 964-5442
ir@medicenna.com
FAQ
What were the voting results for Medicenna's (MDNAF) 2025 annual shareholder meeting?
Who are the current board members of Medicenna (MDNAF) after the 2025 annual meeting?
What percentage of votes did Dr. Fahar Merchant receive at Medicenna's 2025 shareholder meeting?
What changes occurred in Medicenna's board composition at the 2025 annual meeting?
